Kanaoka Koshiro, Iwanaga Yoshitaka, Takegawa Koki, Fujimoto Wataru, Nishioka Yuichi, Myojin Tomoya, Okada Katsuki, Noda Tatsuya, Imamura Tomoaki, Miyamoto Yoshihiro
Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara, Japan.
Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan; Department of Cardiology, Sakurabashi-Watanabe Hospital, Osaka, Osaka, Japan.
JACC Asia. 2025 Jun;5(6):786-795. doi: 10.1016/j.jacasi.2025.01.015. Epub 2025 Apr 8.
Few studies have provided nationwide, longitudinal data on practice patterns of guideline-directed medical therapy (GDMT) for heart failure.
The authors aimed to clarify the doses and patterns of up-titration or discontinuation of GDMT following admission for acute heart failure and to determinants associated with its continuation in Japan.
We retrospectively included data, from the Japanese nationwide health insurance claims database, of patients hospitalized for acute heart failure without a recent history of hospitalization. Patients initiated on GDMTs during hospitalization were followed up for 12 months. We analyzed patient baseline characteristics associated with continuation 12 months after discharge by using a logistic regression model.
Of 791,917 included patients, 405,605 (51.2%) were initiated on ≥1 GDMTs during the index hospitalization. These therapies were frequently discontinued within 3 months of discharge. The proportions of patients for whom the target dose was achieved at 12 months were 10.5%, 7.6%, 8.3%, 23.1%, 7.4%, and 60.2% for beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitor, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors, respectively. Beta-blockers and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitor were more likely to be discontinued for older patients with anemia and dementia, whereas mineralocorticoid receptor antagonists were more likely to be discontinued for patients with chronic kidney disease, compared with other GDMT categories.
Initiation and up-titration of GDMTs were insufficient in nationwide clinical practice. Our results may help clinicians improve titration of GDMTs.
很少有研究提供关于心力衰竭指南指导药物治疗(GDMT)的全国性纵向实践数据。
作者旨在阐明急性心力衰竭入院后GDMT的滴定剂量和模式以及停药情况,并确定日本与GDMT持续使用相关的决定因素。
我们回顾性纳入了日本全国医疗保险索赔数据库中因急性心力衰竭住院且近期无住院史的患者数据。对住院期间开始使用GDMT的患者进行了12个月的随访。我们使用逻辑回归模型分析了与出院后12个月持续使用相关的患者基线特征。
在纳入的791,917例患者中,405,605例(51.2%)在首次住院期间开始使用≥1种GDMT。这些治疗在出院后3个月内经常停药。在12个月时达到目标剂量的患者比例,β受体阻滞剂为10.5%,血管紧张素转换酶抑制剂为7.6%,血管紧张素受体阻滞剂为8.3%,血管紧张素受体脑啡肽酶抑制剂为23.1%,盐皮质激素受体拮抗剂为7.4%,钠-葡萄糖协同转运蛋白2抑制剂为60.2%。与其他GDMT类别相比,贫血和痴呆的老年患者更有可能停用β受体阻滞剂和血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂/血管紧张素受体脑啡肽酶抑制剂,而慢性肾脏病患者更有可能停用盐皮质激素受体拮抗剂。
在全国临床实践中,GDMT的起始和滴定不足。我们的结果可能有助于临床医生改善GDMT的滴定。